This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Radiopharmaceuticals Market

Market Insights on Radiopharmaceuticals covering sales outlook, demand forecast & up-to-date key trends

Radiopharmaceuticals Market By Radioisotope Type (Technetium-99, Fluorine-18, Iodine-131, Leutetium-177), Application (Oncology, Cardiology, Gastroenterology, Neuroendocrinology, Neurology, Nephrology), Source (Cyclotrons, Nuclear Reactors) & Region - Forecast 2021 - 2031

Radiopharmaceuticals Market Snapshot

As per Future Market Insights (FMI) analysis, the radiopharmaceuticals market value will total US$ 6107.2 Mn in 2021. Driven by rising prevalence of cancer and cardiovascular diseases, the radiopharmaceuticals market will register steady year-on-year growth CAGR of 4.90% in 2021.

Regionally, North America will contribute over 47% of global market share owing to the increasing prevalence of cancer cases and expansion of healthcare sector in the U.S. and Canada.

As per FMI, Siemens AG (Siemens Healthineers), General Electric Co. (GE Healthcare), Curium, Lantheus Holdings, Inc., and Eckert & Ziegler are identified as prominent players. Leading players contribute nearly 90% of revenue share in the global radiopharmaceuticals market.

Customize this Report

Let us know your requirement to get
100% FREE customization

Key Points Covered in Radiopharmaceuticals Market Study

  • Market estimates and forecast 2021-2031
  • Key drivers and restraints impacting market growth
  • Segment-wise, Country-wise, and Region-wise Analysis
  • Competition Mapping and Benchmarking
  • Brand share and Market Share Analysis
  • Key Radioisotope Innovations and Regulatory Climate
  • COVID-19 Impact on Radiopharmaceuticals market and How to Navigate
  • Recommendation on Key Winning Strategies

Radiopharmaceuticals Market Download Report Brochure

2016-2020 Global Radiopharmaceuticals Market Outlook in Comparison to 2021-2031 Forecast

Improving penetration of radio-therapeutics is expected to be the major driver of the radiopharmaceuticals market. Radiopharmaceuticals are increasingly used in the diagnosis and treatment of several diseases such as cancer, cardiovascular diseases, and neurological disorders.

Owing to characteristics of radioactive decay and ability of targeted therapeutic irradiation, radiopharmaceuticals are extensively used for the treatment of these diseases. However, unprecedented outbreak of COVID-19 severely impacted the growth of the market.

Production of radioisotopes was disrupted across the globe and research activities were halted. Disruption in the demand and supply chain resulted in the drop of global market value.

Nonetheless, FMI predicts the global sales to be up by 4.66% CAGR during the forecast period of 2021 and 2031. Increasing application of nuclear medicine in oncology will create lucrative opportunities by the end of 2031.

Rapid introduction of advanced technologies in nuclear imaging systems such as SPECT and Positron Emission Tomography (PET) will significantly contribute to market growth. Increasing research and development from leading players is aiding the growth of radiopharmaceuticals market.

For instance, GE Healthcare introduced cloud and IT based solutions and apps to connect medical imaging with analytics and insights. Increasing clinical applications of radiopharmaceuticals in oncology, cardiology, endocrinology, and neurology are improving the market growth.

Additionally, increased funding and favorable initiatives from the government will bolster the demand of radiopharmaceuticals across the globe, reaching a valuation of US$ 6107.2 Mn in 2021.

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

Focus on Developing Centralized Pharmacies Bolstering Growth

The radiopharmaceutical industry has a lack of formalized good manufacturing practice (GMP) guidelines along with stringent policies governing the use of radiopharmaceuticals.

However, to address the quality assurance concerns, nuclear medicine physicians are encouraging establishing centralized radio-pharmacies.

This is due to the growing interest from administrators and legislators in context with regulations for radiopharmaceuticals, Positron Emission Tomography (PET), and for clinical trials.

A centralized radio pharmacy model enforces several advantages to patients as well as governing bodies including minimizing the radiation exposure with ability to dispense patient specific prescription, delivering specified products from all sources and services available.

These initiatives, in turn, are expected to accelerate the market growth over the forecast period.

Country-wise Insights

Why is the U.S. the Most Lucrative Market for Radiopharmaceuticals?

Growth of radiopharmaceuticals market across the U.S. is attributed to the rising prevalence of cancer and cardiovascular diseases in the country. Growing geriatric population and unhealthy living habits resulting in increasing cases of cancer and obesity have improved the sales of nuclear medicines.

Adoption of novel technologies for radioisotope production to treat these diseases is anticipated to bolster the growth of radiopharmaceuticals in the country. According to American Heart Association, around 17.3 million people die each year due to cardiovascular disease.

Radiopharmaceuticals provides an upper hand to the radiologists for the treatment of these diseases. Targeted therapies and advanced technology integrated in cyclotrons for the treatment of cardiovascular disease and cancer will improve the demand for radiopharmaceuticals in the U.S.

Based on these aforementioned factors, the U.S. will lead the North America radiopharmaceuticals market during the forecast period, accounting for over 45% of market share.

Why is the Demand for Radiopharmaceuticals Rising in India?

Expansion of the healthcare sector and adoption of advanced technology are the major factor driving the growth of radiopharmaceuticals market in India. Alongside this, prevalence of cancer cases in the country have bolstered the adoption of targeted therapies and improved the production of radioisotopes.

Increasing preference for non-invasive therapies in India and high efficacy that radiopharmaceuticals provide are the chief reason why radiopharmaceuticals is thriving. Government and private healthcare companies are increasing the funding and research & development activities to develop efficient targeted therapies with less side-effects.

Incorporation of cutting-edge technologies to develop advanced radiotracers for the treatment of cancer and cardiovascular disease are aiding the growth. Several research programs initiated by National Cancer Institute have improved the production and adoption of radioisotopes for the treatment of cancer across India.

For instance, in 2018, the U.S. Food and Drug Administration approved the lutetium Lu 177-dotatate for the treatment of certain cancerous neuroendocrine tumours affecting the digestive tract.

What are the Factors Fueling Demand for Radiopharmaceuticals in Germany?

As per FMI’s analysis, Germany is anticipated to register healthy growth over the forecast period. Germany is anticipated to be the key region leading the growth of Europe’s radiopharmaceuticals market.

Rising adoption of novel technologies including radiotherapy and adoption of radioisotope for cancer treatment have bolstered the demand of radiopharmaceuticals across Germany. Thanks to the presence of leading players across the country, application of nuclear medicine in radiopharmaceuticals is increasing with increasing research & development activities across the country.

Advent of novel technologies such as advanced PET-computed tomography and positron emission tomography-magnetic resonance are facilitating the rising demand of non-invasive therapies for cancer across the country.

Increasing mortality rate in the country due to cancer have compelled the healthcare professionals and governing bodies to improve radioisotope production for usage in molecular imaging and in therapeutic nuclear medicines.

For instance, in 2018, Advancing Nuclear Medicine consortium, led by the Nuclear Research and Consultancy Group (NRG), was awarded a USD7.7 million subsidies to develop FIELD-LAB. This initiative intended to accelerate the development and introduction of new radiopharmaceuticals.

Why is Demand for Radiopharmaceuticals Rising the U.K.?

The U.K. is expected to be a dominant country in Europe, anticipated to account for maximum share in Europe radiopharmaceuticals market.

Rising prevalence of cancer in the U.K. resulted in burgeoning production of radioisotopes to develop advanced molecular imaging and therapies for the cancer treatment. Advantages of radiopharmaceuticals such as high efficacy and non-invasive external monitoring have increased radioisotope production

According to the Cancer Research UK report, approximately 367,167 cases of cancers are diagnosed in the U.K. each year and around 166,000 cancer death recorded every year. Rising situations like this is anticipated to boost the growth of radiopharmaceuticals market across the country.

Expansion of healthcare infrastructure and increasing research on the development of non-invasive targeted therapies to reduce the burden will significantly boost radiopharmaceuticals demand in the U.K.

Growing interest of healthcare professionals, administrators, and legislators in the context with norms for radiopharmaceuticals, positron emission tomography, and clinical trials will certainly aid the market growth.

Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

Category-wise Insights

Which Radioisotope Will Dominate the Radiopharmaceuticals Market?

Future Market Insights estimates, in terms of radioisotopes technetium-99 will dominate the segment during the assessment period.

As technetium-99 is extensively used in over 85% of the total diagnostic imaging procedure in nuclear medicine, it is anticipated to remain highly preferred radioisotope in the radiopharmaceuticals market.

Growth in demand for technetium-99 is attributed to the long shelf life to perform medical examinations to be done on the patient and protracted half-life.

Why are Cyclotrons Considered Primary Source for Radiopharmaceuticals?

Based on source, the market is segmented into cyclotrons and nuclear reactors. As per Future Market Insights, cyclotrons are expected to dominate the market. Increasing cases of cancer and thyroid across the globe, have increased the application of nuclear medicine in radiopharmaceuticals market.

Widespread availability of the PET scanning machines and PET cyclotron & radiopharmaceutical facility have bolstered the segment growth over the past few years. Rising cases of cancer across the globe will increase the adoption of cyclotron as adoption of radioisotopes increases for the treatment of cancer.

Radiopharmaceuticals are produced either using cyclotrons or in nuclear reactors. The former is expected to hold over 2/3rd of the radiopharmaceuticals market share throughout the assessment period.

Benefit of using cyclotron is the possibility of on-site production of radionuclides of interest which propels the market for radiopharmaceuticals even further. Hence, cyclotrons will dominate the segment over the forecast period, boosting market demand.

Which is the Chief Application of Radiopharmaceuticals?

Rising prevalence of cancer and cardiovascular diseases such as coronary heart disease, heart failure, across the globe are providing a certain boost to the market growth.

Increasing cases of lifestyle disorder, obesity, and tumor due to unhealthy habits among elder population are the major drivers accelerating the demand for radiopharmaceuticals. As per FMI, increasing application in oncology due to rising cases of breast cancer, lung cancer, and prostate cancer will propel the segment growth.

Rising application of nuclear medicine in oncology and cardiology are the chief drivers for the growth of the market. As per American Cancer Society, 1.9 million new cancer cases were reported in 2021, and nearly 608,570 people died due to cancer in the U.S.

With rising new cancer cases healthcare professionals are developing advanced new techniques to develop nuclear medicine for the treatment. Rapid introduction of advanced techniques in radiopharmaceuticals to treat cancer will propel the growth.

Radiopharmaceuticals play an imperative role in the diagnosis and treatment of cancer by providing better understanding of disease staging. FMI estimates, increasing application of nuclear medicine in oncology will garner over 50% of the global market value through 2031.

Competitive Landscape

Severe competition among the key players have led to market consolidation, opines Future Market Insights. Siemens AG, G E Healthcare, Curium, Lantheus Holdings Inc., and Eckert & Ziegler are the top 5 players dominating the market.

Nearly 90% of the global market share is held by these top 5 aforementioned players. Offering advanced technology and nuclear medicines for the treatment are among the winning strategies adopted by the top players.

Some of the leading companies such as GE Healthcare and Siemens Healthcare are focusing on introducing new product based technologies, pharmaceutical services, and IT based solutions maintaining their lead in the industry.

  • In March 2021, Aktis Oncology, a biotechnology company developing a novel class of targeted radiopharmaceuticals to treat a broad range of solid tumor cancer cases, announced the completion of a series for solid tumors.
  • In November 2020, Canadian radiopharmaceuticals leading company, Fusion Pharmaceuticals announced the collaboration with Anglo-Swedish Pharma leader AstraZeneca to commercialize and develop next-generation alpha emitting radiopharmaceuticals and combination therapies for the treatment of cancer.

Scope of Report

Attribute

Details

Forecast Period

2021-2031

Historical Data Available for

2016-2020

Market Analysis

USD Million for Value

Key Regions Covered

North America, Western Europe, Eastern Europe, Asia Pacific excluding Japan. Japan, and Middle East & Africa

Key Countries Covered

US, Canada, Germany, U.K., France, Italy, Spain, Russia, China, Japan, South Korea, India, Thailand, Malaysia, Indonesia, Australia, New Zealand, GCC Countries, Turkey, Northern Africa, and South Africa

Key Segments Covered

Radioisotope, Application, Source, End-user, and Regions

Key Companies Profiled

  • Siemens AG
  • Positron Corporation
  • Novartis (Advanced Accelerator Applications)
  • Curium
  • GE Healthcare
  • Lantheus Holdings Inc.
  • Sotera Health LLC
  • Bayer AG
  • Eckert & Ziegler
  • Others

Report Coverage

Market Forecast, Company Share Analysis, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives

Customization & Pricing

Available upon Request

Radiopharmaceuticals Market by Category

By Radioisotope Type:

  • Technetium-99
  • Fluorine-18
  • Iodine-131
  • Leutetium-177
  • Yttrium-90
  • Gallium-68
  • Gallium-67
  • Rubidium-82
  • Iodine-123
  • Iodine-125
  • Indium-111
  • Others

By Application:

  • Oncology
  • Cardiology
  • Gastroenterology
  • Neuroendocrinology
  • Neurology
  • Nephrology
  • Others

By Source:

  • Cyclotrons
  • Nuclear Reactors

By End-User:

  • Hospitals
  • Diagnostic Imaging Centers
  • Ambulatory Surgical Centers
  • Cancer Research Institute

By Region:

  • North America
  • Latin America
  • Western Europe
  • Eastern Europe
  • Asia Pacific excluding Japan
  • Japan
  • Middle East & Africa (MEA)

Frequently Asked Questions

The radiopharmaceuticals market is expected to surpass a valuation of US$ 6,107.2 Bn in 2021

The radiopharmaceuticals market witnessed steady growth at 5.33% CAGR between 2016 and 2020.

Siemens AG, General Electric Co. (GE Healthcare), Curium, Lantheus Holdings, Inc., and Eckert & Ziegler are the top players leading the radiopharmaceuticals market.

North America accounted for over 47% of global radiopharmaceuticals market, and is expected to hold major share during the forecast period.

Europe radiopharmaceuticals market will exhibit sluggish growth at 4.9% CAGR during the forecast period.

Top countries in terms of radiopharmaceuticals sales are the U.S., the U.K., Germany, India, and China.

Leading players of global radiopharmaceuticals market is expected to contribute nearly 90% of total market share.

Japan, in 2020, accounted for over 11% market share of global radiopharmaceuticals market in 2021.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Global Market Share Analysis

    1.3. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Macro-Economic Factors

        3.1.1. Increasing healthcare expenditure as a percentage of GDP

        3.1.2. Rise in Aging population

    3.2. Forecast Factors - Relevance & Impact

        3.2.1. Increasing Installed base for PET and SPECT Scanners

        3.2.2. Increasing Incidence of Cancer

        3.2.3. Increasing Diagnosis Rate

    3.3. Market Dynamics

        3.3.1. Opportunity Analysis

        3.3.2. Drivers

        3.3.3. Restraints

        3.3.4. Trends

4. Market Context

    4.1. Reimbursement Scenario

    4.2. Key Regulations

    4.3. Value Chain Analysis

5. Global Radiopharmaceuticals Market Demand (Size in US$ Mn) Analysis 2016 - 2020 and Forecast, 2021 - 2031

    5.1. Historical Market Value (US$ Mn) Analysis, 2016 - 2020

    5.2. Current and Future Market Value (US$ Mn) Projections, 2021 - 2031

        5.2.1. Y-o-Y Growth Trend Analysis

        5.2.2. Absolute $ Opportunity Analysis

    5.3. Market Value Growth Comparison

6. Global Radiopharmaceuticals Market Analysis 2016 - 2020 and Forecast 2021 - 2031, by Radioisotope 

    6.1. Introduction / Key Findings

    6.2. Historical Market Size (US$ Mn) Analysis By Radioisotope, 2016–2020

    6.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Radioisotope, 2021 - 2031

        6.3.1. Technetium-99

        6.3.2. Fluorine-18

        6.3.3. Iodine-131

        6.3.4. Leutetium-177

        6.3.5. Yttrium-90

        6.3.6. Gallium-68

        6.3.7. Gallium-67

        6.3.8. Rubidium-82

        6.3.9. Iodine-123

        6.3.10. Iodine-125

        6.3.11. Indium-111

        6.3.12. Others

    6.4. Market Attractiveness Analysis By Radioisotope

7. Global Radiopharmaceuticals Market Analysis 2016 - 2020 and Forecast 2021 - 2031, by Application 

    7.1. Introduction / Key Findings

    7.2. Historical Market Size (US$ Mn) Analysis By Application, 2016–2020

    7.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Application, 2021 - 2031

        7.3.1. Oncology

        7.3.2. Cardiology

        7.3.3. Gastroenterology

        7.3.4. Neuroendocrinology

        7.3.5. Neurology

        7.3.6. Nephrology

        7.3.7. Others

    7.4. Market Attractiveness Analysis By Application

8. Global Radiopharmaceuticals Market Analysis 2016 - 2020 and Forecast 2021 - 2031, by Source 

    8.1. Introduction / Key Findings

    8.2. Historical Market Size (US$ Mn) Analysis By Source, 2016–2020

    8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Source, 2021 - 2031

        8.3.1. Cyclotrons

        8.3.2. Nuclear Reactors

    8.4. Market Attractiveness Analysis By Source

9. Global Radiopharmaceuticals Market Analysis 2016 - 2020 and Forecast 2021 - 2031, by End User

    9.1. Introduction / Key Findings

    9.2. Historical Market Size (US$ Mn) Analysis By End User, 2016–2020

    9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By End User, 2021 - 2031

        9.3.1. Hospitals

        9.3.2. Diagnostic Imaging Centers

        9.3.3. Ambulatory Surgical Centers

        9.3.4. Cancer Research Institute

    9.4. Market Attractiveness Analysis By End User

10. Global Radiopharmaceuticals Market Analysis 2016 - 2020 and Forecast 2021 - 2031, by Region

    10.1. Introduction / Key Findings

    10.2. Historical Market Size (US$ Mn) Analysis By Region, 2016–2020

    10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Region, 2021 - 2031

        10.3.1. North America

        10.3.2. Latin America

        10.3.3. Western Europe

        10.3.4. Eastern Europe

        10.3.5. APEJ

        10.3.6. Japan

        10.3.7. MEA

    10.4. Market Attractiveness Analysis By Region

11. North America Radiopharmaceuticals Market Analysis 2016 - 2020 and Forecast 2021 - 2031

    11.1. Introduction

    11.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2016–2020

    11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2021 - 2031

        11.3.1. By Country

            11.3.1.1. U.S.

            11.3.1.2. Canada

        11.3.2. By Radioisotope

        11.3.3. By Application

        11.3.4. By Source

        11.3.5. By End User

    11.4. Market Attractiveness Analysis

        11.4.1. By Country

        11.4.2. By Radioisotope

        11.4.3. By Application

        11.4.4. By Source

        11.4.5. By End User

12. Latin America Radiopharmaceuticals Market Analysis 2016 - 2020 and Forecast 2021 - 2031

    12.1. Introduction

    12.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2016–2020

    12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2021 - 2031

        12.3.1. By Country

            12.3.1.1. Brazil

            12.3.1.2. Mexico

            12.3.1.3. Rest of Latin America

        12.3.2. By Radioisotope

        12.3.3. By Application

        12.3.4. By Source

        12.3.5. By End User

    12.4. Market Attractiveness Analysis

        12.4.1. By Country

        12.4.2. By Radioisotope

        12.4.3. By Application

        12.4.4. By Source

        12.4.5. By End User

13. Western Europe Radiopharmaceuticals Market Analysis 2016 - 2020 and Forecast 2021 - 2031

    13.1. Introduction

    13.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2016–2020

    13.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2021 - 2031

        13.3.1. By Country

            13.3.1.1. Germany

            13.3.1.2. UK

            13.3.1.3. France

            13.3.1.4. Spain

            13.3.1.5. Italy

            13.3.1.6. Nordic Countries

            13.3.1.7. Benelux

            13.3.1.8. Rest of WE

        13.3.2. By Radioisotope

        13.3.3. By Application

        13.3.4. By Source

        13.3.5. By End User

    13.4. Market Attractiveness Analysis

        13.4.1. By Country

        13.4.2. By Radioisotope

        13.4.3. By Application

        13.4.4. By Source

        13.4.5. By End User

14. Eastern Europe Radiopharmaceuticals Market Analysis 2016 - 2020 and Forecast 2021 - 2031

    14.1. Introduction

    14.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2016–2020

    14.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2021 - 2031

        14.3.1. By Country

            14.3.1.1. Russia

            14.3.1.2. Poland

            14.3.1.3. Rest of EE

        14.3.2. By Radioisotope

        14.3.3. By Application

        14.3.4. By Source

        14.3.5. By End User

    14.4. Market Attractiveness Analysis

        14.4.1. By Country

        14.4.2. By Radioisotope

        14.4.3. By Application

        14.4.4. By Source

        14.4.5. By End User

15. APEJ Radiopharmaceuticals Market Analysis 2016 - 2020 and Forecast 2021 - 2031

    15.1. Introduction

    15.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2016–2020

    15.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2021 - 2031

        15.3.1. By Country

            15.3.1.1. China

            15.3.1.2. India

            15.3.1.3. Australia & NZ

            15.3.1.4. ASEAN

            15.3.1.5. Rest of APEJ

        15.3.2. By Radioisotope

        15.3.3. By Application

        15.3.4. By Source

        15.3.5. By End User

    15.4. Market Attractiveness Analysis

        15.4.1. By Country

        15.4.2. By Radioisotope

        15.4.3. By Application

        15.4.4. By Source

        15.4.5. By End User

16. Japan Radiopharmaceuticals Market Analysis 2016 - 2020 and Forecast 2021 - 2031

    16.1. Introduction

    16.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2016–2020

    16.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2021 - 2031

        16.3.1. By Radioisotope

        16.3.2. By Application

        16.3.3. By Source

        16.3.4. By End User

    16.4. Market Attractiveness Analysis

        16.4.1. By Radioisotope

        16.4.2. By Application

        16.4.3. By Source

        16.4.4. By End User

17. Middle East and Africa Radiopharmaceuticals Market Analysis 2016 - 2020 and Forecast 2021 - 2031

    17.1. Introduction

    17.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2016–2020

    17.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2021 - 2031

        17.3.1. By Country

            17.3.1.1. GCC Countries

            17.3.1.2. South Africa

            17.3.1.3. Rest of MEA

        17.3.2. By Radioisotope

        17.3.3. By Application

        17.3.4. By Source

        17.3.5. By End User

    17.4. Market Attractiveness Analysis

        17.4.1. By Country

        17.4.2. By Radioisotope

        17.4.3. By Application

        17.4.4. By Source

        17.4.5. By End User

18. Competition Analysis

    18.1. Competition Dashboard

    18.2. Competition Benchmarking

    18.3. Competition Deep pe (Tentative List)

        18.3.1. Siemens AG (Siemens Healthineers)

            18.3.1.1. Overview

            18.3.1.2. Service Portfolio

            18.3.1.3. Profitability by Market Segments (Service/Channel/Region)

            18.3.1.4. Sales Footprint

            18.3.1.5. Strategy Overview

                18.3.1.5.1. Marketing Strategy

                18.3.1.5.2. Service Strategy

                18.3.1.5.3. Channel Strategy

        18.3.2. Positron Corporation

            18.3.2.1. Overview

            18.3.2.2. Service Portfolio

            18.3.2.3. Profitability by Market Segments (Service/Channel/Region)

            18.3.2.4. Sales Footprint

            18.3.2.5. Strategy Overview

                18.3.2.5.1. Marketing Strategy

                18.3.2.5.2. Service Strategy

                18.3.2.5.3. Channel Strategy

        18.3.3. Novartis (Advanced Accelerator Applications)

            18.3.3.1. Overview

            18.3.3.2. Service Portfolio

            18.3.3.3. Profitability by Market Segments (Service/Channel/Region)

            18.3.3.4. Sales Footprint

            18.3.3.5. Strategy Overview

                18.3.3.5.1. Marketing Strategy

                18.3.3.5.2. Service Strategy

                18.3.3.5.3. Channel Strategy

        18.3.4. Curium

            18.3.4.1. Overview

            18.3.4.2. Service Portfolio

            18.3.4.3. Profitability by Market Segments (Service/Channel/Region)

            18.3.4.4. Sales Footprint

            18.3.4.5. Strategy Overview

                18.3.4.5.1. Marketing Strategy

                18.3.4.5.2. Service Strategy

                18.3.4.5.3. Channel Strategy

        18.3.5. GE Healthcare

            18.3.5.1. Overview

            18.3.5.2. Service Portfolio

            18.3.5.3. Profitability by Market Segments (Service/Channel/Region)

            18.3.5.4. Sales Footprint

            18.3.5.5. Strategy Overview

                18.3.5.5.1. Marketing Strategy

                18.3.5.5.2. Service Strategy

                18.3.5.5.3. Channel Strategy

        18.3.6. Lantheus Holdings, Inc.

            18.3.6.1. Overview

            18.3.6.2. Service Portfolio

            18.3.6.3. Profitability by Market Segments (Service/Channel/Region)

            18.3.6.4. Sales Footprint

            18.3.6.5. Strategy Overview

                18.3.6.5.1. Marketing Strategy

                18.3.6.5.2. Service Strategy

                18.3.6.5.3. Channel Strategy

        18.3.7. Sotera Health LLC (Nordion, Inc)

            18.3.7.1. Overview

            18.3.7.2. Service Portfolio

            18.3.7.3. Profitability by Market Segments (Service/Channel/Region)

            18.3.7.4. Sales Footprint

            18.3.7.5. Strategy Overview

                18.3.7.5.1. Marketing Strategy

                18.3.7.5.2. Service Strategy

                18.3.7.5.3. Channel Strategy

        18.3.8. Bayer AG

            18.3.8.1. Overview

            18.3.8.2. Service Portfolio

            18.3.8.3. Profitability by Market Segments (Service/Channel/Region)

            18.3.8.4. Sales Footprint

            18.3.8.5. Strategy Overview

                18.3.8.5.1. Marketing Strategy

                18.3.8.5.2. Service Strategy

                18.3.8.5.3. Channel Strategy

        18.3.9. Eckert & Ziegler

            18.3.9.1. Overview

            18.3.9.2. Service Portfolio

            18.3.9.3. Profitability by Market Segments (Service/Channel/Region)

            18.3.9.4. Sales Footprint

            18.3.9.5. Strategy Overview

                18.3.9.5.1. Marketing Strategy

                18.3.9.5.2. Service Strategy

                18.3.9.5.3. Channel Strategy

19. Assumptions and Acronyms Used

20. Research Methodology

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

Table 01: Global Radiopharmaceuticals Market Value (US$ Mn) Growth Comparison

Table 02: Global Radiopharmaceuticals Market Value (US$ Mn) Analysis and Opportunity Assessment 2021 - 2031, By Radioisotope 

Table 03: Global Radiopharmaceuticals Market Value (US$ Mn) Analysis and Opportunity Assessment 2021 - 2031, By Application 

Table 04: Global Radiopharmaceuticals Market Value (US$ Mn) Analysis and Opportunity Assessment 2021 - 2031, By Source 

Table 05: Global Radiopharmaceuticals Market Value (US$ Mn) Analysis and Opportunity Assessment 2021 - 2031, By End User 

Table 06: Global Radiopharmaceuticals Market Value (US$ Mn) Analysis and Opportunity Assessment 2021 - 2031, By Region 

Table 07: North America Radiopharmaceuticals Market Value (US$ Mn) Analysis 2016 - 2020 and Forecast 2021 - 2031, By Country

Table 08: North America Radiopharmaceuticals Market Value (US$ Mn) Analysis 2016 - 2020 and Forecast 2021 - 2031, By Radioisotope

Table 09: North America Radiopharmaceuticals Market Value (US$ Mn) Analysis 2016 - 2020 and Forecast 2021 - 2031, By Application

Table 10: North America Radiopharmaceuticals Market Value (US$ Mn) Analysis 2016 - 2020 and Forecast 2021 - 2031, By Source

Table 11: North America Radiopharmaceuticals Market Value (US$ Mn) Analysis 2016 - 2020 and Forecast 2021 - 2031, By End User

Table 12: Latin America Radiopharmaceuticals Market Value (US$ Mn) Analysis 2016 - 2020 and Forecast 2021 - 2031, By Country

Table 13: Latin America Radiopharmaceuticals Market Value (US$ Mn) Analysis 2016 - 2020 and Forecast 2021 - 2031, By Radioisotope

Table 14: Latin America Radiopharmaceuticals Market Value (US$ Mn) Analysis 2016 - 2020 and Forecast 2021 - 2031, By Application

Table 15: Latin America Radiopharmaceuticals Market Value (US$ Mn) Analysis 2016 - 2020 and Forecast 2021 - 2031, By Source

Table 16: Latin America Radiopharmaceuticals Market Value (US$ Mn) Analysis 2016 - 2020 and Forecast 2021 - 2031, By End User

Table 17: Western Europe Radiopharmaceuticals Market Value (US$ Mn) Analysis 2016 - 2020 and Forecast 2021 - 2031, By Country

Table 18: Western Europe Radiopharmaceuticals Market Value (US$ Mn) Analysis 2016 - 2020 and Forecast 2021 - 2031, By Radioisotope

Table 19: Western Europe Radiopharmaceuticals Market Value (US$ Mn) Analysis 2016 - 2020 and Forecast 2021 - 2031, By Application

Table 20: Western Europe Radiopharmaceuticals Market Value (US$ Mn) Analysis 2016 - 2020 and Forecast 2021 - 2031, By Source

Table 21: Western Europe Radiopharmaceuticals Market Value (US$ Mn) Analysis 2016 - 2020 and Forecast 2021 - 2031, By End User

Table 22: Eastern Europe Radiopharmaceuticals Market Value (US$ Mn) Analysis 2016 - 2020 and Forecast 2021 - 2031, By Country

Table 23: Eastern Europe Radiopharmaceuticals Market Value (US$ Mn) Analysis 2016 - 2020 and Forecast 2021 - 2031, By Radioisotope

Table 24: Eastern Europe Radiopharmaceuticals Market Value (US$ Mn) Analysis 2016 - 2020 and Forecast 2021 - 2031, By Application

Table 25: Eastern Europe Radiopharmaceuticals Market Value (US$ Mn) Analysis 2016 - 2020 and Forecast 2021 - 2031, By Source

Table 26: Eastern Europe Radiopharmaceuticals Market Value (US$ Mn) Analysis 2016 - 2020 and Forecast 2021 - 2031, By End User

Table 27: APEJ Radiopharmaceuticals Market Value (US$ Mn) Analysis 2016 - 2020 and Forecast 2021 - 2031, By Country

Table 28: APEJ Radiopharmaceuticals Market Value (US$ Mn) Analysis 2016 - 2020 and Forecast 2021 - 2031, By Radioisotope

Table 29: APEJ Radiopharmaceuticals Market Value (US$ Mn) Analysis 2016 - 2020 and Forecast 2021 - 2031, By Application

Table 30: APEJ Radiopharmaceuticals Market Value (US$ Mn) Analysis 2016 - 2020 and Forecast 2021 - 2031, By Source

Table 31: APEJ Radiopharmaceuticals Market Value (US$ Mn) Analysis 2016 - 2020 and Forecast 2021 - 2031, By End User

Table 32: Japan Radiopharmaceuticals Market Value (US$ Mn) Analysis 2016 - 2020 and Forecast 2021 - 2031, By Radioisotope

Table 33: Japan Radiopharmaceuticals Market Value (US$ Mn) Analysis 2016 - 2020 and Forecast 2021 - 2031, By Application

Table 34: Japan Radiopharmaceuticals Market Value (US$ Mn) Analysis 2016 - 2020 and Forecast 2021 - 2031, By Source

Table 35: Japan Radiopharmaceuticals Market Value (US$ Mn) Analysis 2016 - 2020 and Forecast 2021 - 2031, By End User

Table 36: MEA Radiopharmaceuticals Market Value (US$ Mn) Analysis 2016 - 2020 and Forecast 2021 - 2031, By Country

Table 37: MEA Radiopharmaceuticals Market Value (US$ Mn) Analysis 2016 - 2020 and Forecast 2021 - 2031, By Radioisotope

Table 38: MEA Radiopharmaceuticals Market Value (US$ Mn) Analysis 2016 - 2020 and Forecast 2021 - 2031, By Application

Table 39: MEA Radiopharmaceuticals Market Value (US$ Mn) Analysis 2016 - 2020 and Forecast 2021 - 2031, By Source

Table 40: MEA Radiopharmaceuticals Market Value (US$ Mn) Analysis 2016 - 2020 and Forecast 2021 - 2031, By End User 2031

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

Figure 01: Global Radiopharmaceuticals Market Revenue Share by Radioisotope, 2021E & 2031F

Figure 02: Global Radiopharmaceuticals Market Revenue Share by Application, 2021E & 2031F

Figure 03: Global Radiopharmaceuticals Market Revenue Share by Source, 2021E & 2031F

Figure 04: Global Radiopharmaceuticals Market Revenue Share by End User, 2021E & 2031F

Figure 05: Global Radiopharmaceuticals Market Revenue Share by Region, 2021E & 2031F

Figure 06: Radiopharmaceuticals Market Value Analysis and Forecast 2021 – 2031 (US$ Mn)

Figure 07: Radiopharmaceuticals Market Value (US$ Mn), 2016 – 2020

Figure 08: Radiopharmaceuticals Market Absolute $ Opportunity (US$ Mn), 2021 - 2031

Figure 09: Comparison February 2017 and October 2021, Y-o-Y Forecast

Figure 10: Global Radiopharmaceuticals Market Share Analysis (%), By Radioisotope, 2021 & 2031

Figure 11: Global Radiopharmaceuticals Market Y-o-Y Analysis (%), By Radioisotope, 2021 - 2031

Figure 12: Global Radiopharmaceuticals Market Attractiveness Analysis by Radioisotope, 2021 - 2031

Figure 13: Global Radiopharmaceuticals Market Share Analysis (%), By Application, 2021 & 2031

Figure 14: Global Radiopharmaceuticals Market Y-o-Y Analysis (%), By Application, 2021 - 2031

Figure 15: Global Radiopharmaceuticals Market Attractiveness Analysis by Application, 2021 - 2031

Figure 16: Global Radiopharmaceuticals Market Share Analysis (%), By Source, 2021 & 2031

Figure 17: Global Radiopharmaceuticals Market Y-o-Y Analysis (%), By Source, 2021 - 2031

Figure 18: Global Radiopharmaceuticals Market Attractiveness Analysis by Source, 2021 - 2031

Figure 19: Global Radiopharmaceuticals Market Share Analysis (%), By End User, 2021 & 2031

Figure 20: Global Radiopharmaceuticals Market Y-o-Y Analysis (%), By End User, 2021 - 2031

Figure 21: Global Radiopharmaceuticals Market Attractiveness Analysis by End User, 2021 - 2031

Figure 22: Global Radiopharmaceuticals Market Share Analysis (%), By Region, 2021 & 2031

Figure 23: Global Radiopharmaceuticals Market Y-o-Y Analysis (%), By Region, 2021 - 2031

Figure 24: Global Radiopharmaceuticals Market Attractiveness Analysis by Region, 2021 - 2031

Figure 25: North America Radiopharmaceuticals Market Value Share, By Radioisotope (2021 E)

Figure 26: North America Radiopharmaceuticals Market Value Share, By Application (2021 E)

Figure 27: North America Radiopharmaceuticals Market Value Share, By Source (2021 E)

Figure 28: North America Radiopharmaceuticals Market Value Share, By End User (2021 E)

Figure 29: North America Radiopharmaceuticals Market Value Share, By Country (2021 E)

Figure 30: North America Radiopharmaceuticals Market Value Analysis (US$ Mn), 2016 - 2020

Figure 31: North America Radiopharmaceuticals Market Value Forecast (US$ Mn), 2021 - 2031

Figure 32: North America Radiopharmaceuticals Market Attractiveness Analysis by Radioisotope, 2021 - 2031

Figure 33: North America Radiopharmaceuticals Market Attractiveness Analysis by Application, 2021 - 2031

Figure 34: North America Radiopharmaceuticals Market Attractiveness Analysis by Source, 2021 - 2031

Figure 35: North America Radiopharmaceuticals Market Attractiveness Analysis by End User, 2021 - 2031

Figure 36: North America Radiopharmaceuticals Market Attractiveness Analysis by Region, 2021 - 2031

Figure 37: Latin America Radiopharmaceuticals Market Value Share, By Radioisotope (2021 E)

Figure 38: Latin America Radiopharmaceuticals Market Value Share, By Application (2021 E)

Figure 39: Latin America Radiopharmaceuticals Market Value Share, By Source (2021 E)

Figure 40: Latin America Radiopharmaceuticals Market Value Share, By End User (2021 E)

Figure 41: Latin America Radiopharmaceuticals Market Value Share, By Country (2021 E)

Figure 42: Latin America Radiopharmaceuticals Market Value Analysis (US$ Mn),  2016 - 2020

Figure 43: Latin America Radiopharmaceuticals Market Value Forecast (US$ Mn), 2021 - 2031

Figure 44: Latin America Radiopharmaceuticals Market Attractiveness Analysis by Radioisotope, 2021 - 2031

Figure 45: Latin America Radiopharmaceuticals Market Attractiveness Analysis by Application, 2021 - 2031

Figure 46: Latin America Radiopharmaceuticals Market Attractiveness Analysis by Source, 2021 - 2031

Figure 47: Latin America Radiopharmaceuticals Market Attractiveness Analysis by End User, 2021 - 2031

Figure 48: Latin America Radiopharmaceuticals Market Attractiveness Analysis by Region, 2021 - 2031

Figure 49: Western Europe Radiopharmaceuticals Market Value Share, By Radioisotope (2021 E)

Figure 50: Western Europe Radiopharmaceuticals Market Value Share, By Application (2021 E)

Figure 51: Western Europe Radiopharmaceuticals Market Value Share, By Source (2021 E)

Figure 52: Western Europe Radiopharmaceuticals Market Value Share, By End User (2021 E)

Figure 53: Western Europe Radiopharmaceuticals Market Value Share, By Country (2021 E)

Figure 54: Western Europe Radiopharmaceuticals Market Value Analysis (US$ Mn),  2016 - 2020

Figure 55: Western Europe Radiopharmaceuticals Market Value Forecast (US$ Mn), 2021 - 2031

Figure 56: Western Europe Radiopharmaceuticals Market Attractiveness Analysis by Radioisotope, 2021 - 2031

Figure 57: Western Europe Radiopharmaceuticals Market Attractiveness Analysis by Application, 2021 - 2031

Figure 58: Western Europe Radiopharmaceuticals Market Attractiveness Analysis by Source, 2021 - 2031

Figure 59: Western Europe Radiopharmaceuticals Market Attractiveness Analysis by End User, 2021 - 2031

Figure 60: Western Europe Radiopharmaceuticals Market Attractiveness Analysis by Region, 2021 - 2031

Figure 61: Eastern Europe Radiopharmaceuticals Market Value Share, By Radioisotope (2021 E)

Figure 62: Eastern Europe Radiopharmaceuticals Market Value Share, By Application (2021 E)

Figure 63: Eastern Europe Radiopharmaceuticals Market Value Share, By Source (2021 E)

Figure 64: Eastern Europe Radiopharmaceuticals Market Value Share, By End User (2021 E)

Figure 65: Eastern Europe Radiopharmaceuticals Market Value Share, By Country (2021 E)

Figure 66: Eastern Europe Radiopharmaceuticals Market Value Analysis (US$ Mn),  2016 - 2020

Figure 67: Eastern Europe Radiopharmaceuticals Market Value Forecast (US$ Mn), 2021 - 2031

Figure 68: Eastern Europe Radiopharmaceuticals Market Attractiveness Analysis by Radioisotope, 2021 - 2031

Figure 69: Eastern Europe Radiopharmaceuticals Market Attractiveness Analysis by Application, 2021 - 2031

Figure 70: Eastern Europe Radiopharmaceuticals Market Attractiveness Analysis by Source, 2021 - 2031

Figure 71: Eastern Europe Radiopharmaceuticals Market Attractiveness Analysis by End User, 2021 - 2031

Figure 72: Eastern Europe Radiopharmaceuticals Market Attractiveness Analysis by Region, 2021 - 2031

Figure 73: APEJ Radiopharmaceuticals Market Value Share, By Radioisotope (2021 E)

Figure 74: APEJ Radiopharmaceuticals Market Value Share, By Application (2021 E)

Figure 75: APEJ Radiopharmaceuticals Market Value Share, By Source (2021 E)

Figure 76: APEJ Radiopharmaceuticals Market Value Share, By End User (2021 E)

Figure 77: APEJ Radiopharmaceuticals Market Value Share, By Country (2021 E)

Figure 78: APEJ Radiopharmaceuticals Market Value Analysis (US$ Mn),  2016 - 2020

Figure 79: APEJ Radiopharmaceuticals Market Value Forecast (US$ Mn), 2021 - 2031

Figure 80: APEJ Radiopharmaceuticals Market Attractiveness Analysis by Radioisotope, 2021 - 2031

Figure 81: APEJ Radiopharmaceuticals Market Attractiveness Analysis by Application, 2021 - 2031

Figure 82: APEJ Radiopharmaceuticals Market Attractiveness Analysis by Source, 2021 - 2031

Figure 83: APEJ Radiopharmaceuticals Market Attractiveness Analysis by End User, 2021 - 2031

Figure 84: APEJ Radiopharmaceuticals Market Attractiveness Analysis by Region, 2021 - 2031

Figure 85: Japan Radiopharmaceuticals Market Value Share, By Radioisotope (2021 E)

Figure 86: Japan Radiopharmaceuticals Market Value Share, By Application (2021 E)

Figure 87: Japan Radiopharmaceuticals Market Value Share, By Source (2021 E)

Figure 88: Japan Radiopharmaceuticals Market Value Share, By End User (2021 E)

Figure 89: Japan Radiopharmaceuticals Market Value Analysis (US$ Mn),  2016 - 2020

Figure 90: Japan Radiopharmaceuticals Market Value Forecast (US$ Mn), 2021 - 2031

Figure 91: Japan Radiopharmaceuticals Market Attractiveness Analysis by Radioisotope, 2021 - 2031

Figure 92: Japan Radiopharmaceuticals Market Attractiveness Analysis by Application, 2021 - 2031

Figure 93: Japan Radiopharmaceuticals Market Attractiveness Analysis by Source, 2021 - 2031

Figure 94: Japan Radiopharmaceuticals Market Attractiveness Analysis by End User, 2021 - 2031

Figure 95: MEA Radiopharmaceuticals Market Value Share, By Radioisotope (2021 E)

Figure 96: MEA Radiopharmaceuticals Market Value Share, By Application (2021 E)

Figure 97: MEA Radiopharmaceuticals Market Value Share, By Source (2021 E)

Figure 98: MEA Radiopharmaceuticals Market Value Share, By End User (2021 E)

Figure 99: MEA Radiopharmaceuticals Market Value Share, By Country (2021 E)

Figure 100: MEA Radiopharmaceuticals Market Value Analysis (US$ Mn),  2016 - 2020

Figure 101: MEA Radiopharmaceuticals Market Value Forecast (US$ Mn), 2021 - 2031

Figure 102: MEA Radiopharmaceuticals Market Attractiveness Analysis by Radioisotope, 2021 - 2031

Figure 103: MEA Radiopharmaceuticals Market Attractiveness Analysis by Application, 2021 - 2031

Figure 104: MEA Radiopharmaceuticals Market Attractiveness Analysis by Source, 2021 - 2031

Figure 105: MEA Radiopharmaceuticals Market Attractiveness Analysis by End User, 2021 - 2031

Figure 106: MEA Radiopharmaceuticals Market Attractiveness Analysis by Region, 2021 - 2031

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports

Recommendations

Healthcare

Radiopharmaceuticals Market

Published : August 2021

Healthcare

Oxytocic Pharmaceuticals Market

Published : July 2021

Healthcare

Topical Antibiotic Pharmaceuticals Market

Published : April 2016

Healthcare

Halal Pharmaceuticals Market

Published : February 2016

Google translate

Radiopharmaceuticals Market